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Abstract: Allergic rhinitis (AR) is a chronic disease with an in-
creasing trend in most of the Western Countries. It may significantly
impair the individual quality of life (QoL) and also represents a
social burden for its economic costs. Levocetirizine (XYZAL; UCB
Pharma) as a second generation, nonsedating H1-antihistamine, has
been shown to be clinically effective in patients with AR in different
randomized controlled trials. The XPERT (XYZAL in Persistent
Rhinitis Trial) is the first large, long-term clinical study involving
patients with persistent rhinitis as defined by ARIA (Allergic Rhi-
nitis and its Impact on Asthma). The XPERT was a 6-month
double-blind, placebo-controlled, multicenter, multinational trial in
551 subjects. Adults with persistent rhinitis sensitized to both grass
pollen and house dust mites were randomized to receive levoceti-
rizine 5 mg/d or placebo. Two primary objectives were considered:
comparison of the Rhinoconjunctivitis Quality of Life Questionnaire
(RQLQ) overall score and Total 5 Symptoms Score (rhinorrhea,
sneezing, nasal congestion, and nasal and ocular pruritus) (T5SS)
between active and control group over a period of 4 weeks. As
secondary endpoints, similar evaluations at 1 week and 3, 4, 5, and
6 months, summary scores for a general health status questionnaire
(Medical Outcomes Survey Short Form 36), comorbidities, phar-
macoeconomic and safety evaluations. Levocetirizine significantly
improved both the RQLQ overall score and the T5SS from week 1
to 6 months (P .001). Medical Outcomes Survey Short Form 36
summary scores were also improved in the group treated with
levocetirizine with respect to placebo. Treatment cessation because
of lack of efficacy, comorbidities, and overall costs of disease, and
comorbidities per working patient per month (160.27 vs 108.18)
were lower in the levocetirizine group. In conclusion, levocetirizine
resulted to improve the quality of life and the symptoms related to
AR and also to reduce the overall costs of the disease after 6 months
treatment.
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Allergic rhinitis is a frequent chronic disease that maysignificantly impair health-related quality of life
(HRQoL). Several studies and epidemiological data have
shown that allergic rhinitis has an economically remarkable
impact caused by work days loss, absenteeism, and poor task
performance, with a global reduction in productivity. It is
fundamental to remember the ARIA document published in
20011 where allergic rhinitis is divided into 4 categories: mild
intermittent, moderate/severe intermittent, mild persistent,
and moderate/severe persistent (depending on severity and
duration of symptoms and quality of life). This classification
has been recently confirmed at an international level2 and a
stepwise pharmacologic treatment is proposed on the basis of
ARIA criteria. In all the categories mentioned before, a
treatment based on the use of a second-generation nonsedat-
ing H1-antihistamine is recommended for the management of
allergic rhinitis, according to ARIA guidelines.
Levocetirizine (XYZAL; UCB Pharma, Brussels, Bel-
gium) is an oral, nonsedating H1-antihistamine that proved to
be significantly effective in improving symptoms in patients
with allergic rhinitis; it presents a good safety profile3–8 and,
for all these pharmacologic characteristics, is highly indicated
as a first-line treatment in subjects with persistent allergic
rhinitis (PER). The XYZAL in Persistent Rhinitis Trial
(XPERT) is a remarkable study published in 2004,9 providing
different clinical, HRQoL, and pharmacoeconomic assess-
ments, applied over the long term, and using electronic diary
cards, to evaluate the efficacy of levocetirizine in both
HRQoL and economic aspects.
Two primary outcomes were considered in the trial:
Y To analyze and compare the effects of levocetirizine
versus placebo on HRQoL, as evaluated through the
Rhinoconjunctivitis Quality of Life Questionnaire
(RQLQ) overall score at baseline and after 4 weeks of
treatment;
Y To compare the mean Total 5 Symptoms Score (T5SS;
sum of rhinorrhea, sneezing, nasal congestion, and nasal
and ocular pruritus; score, 0–15), assessed for 24 hours
over a period of 4 weeks of treatment.
Secondary objectives of the study were to compare
RQLQ overall score and symptom scores after 1 week and 3,
4.5, and 6 months of treatment. Other secondary objectives
were as follows:
Y The comparison of the effects on health status as mea-
sured by the Medical Outcomes Survey Short Form 36
(SF-36) questionnaire (physical and mental summary
scores) after periods of 4 weeks, 3 months, 4.5 months,
and 6 months;
Y The evaluation of the rescue medication use over the
6-month treatment period;
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Y The assessment of levocetirizine safety during the
6-month trial period.
The present survey also provided a relevant analysis of
pharmacoeconomic data about the treatment of PER. It is a
large multicenter, randomized, placebo-controlled, double-
blind, parallel group trial, involving more than 500 patients
from 63 centers in 5 European countries (Belgium, France,
Germany, Italy, and Spain); in addition, it is the first long-
term (6-month) trial carried out with an oral H1-antihistamine
in PER, with important consequential implications on guide-
lines criteria use and clinical practice.
In the study, all the patients enrolled were 18 years old
at least and presented symptoms related to PER (defined as
allergic rhinitis symptoms lasting 4 days or more per week for
4 consecutive weeks or more per year). They also presented
positive skin prick test or specific serum IgE (CAP System;
Pharmacia Diagnostic, Uppsala, Sweden) for house dust
mites and one pollen allergen (grass or Parietaria, IgE level
3.5 U/mL) at least. Informed consent was obtained from all
participants and the study was conducted according to good
clinical practice and the Helsinki Declaration in 1996 and
under permission of the respective institutional review
boards. Demographic characteristics of the patients are de-
scribed in Table 1.
Globally considered, 76.4% of patients completed the
study treatment, 80.9% levocetirizine and 71.8% placebo.
Forty-five patients (16.5%) in the placebo group dropped out
for absent or insufficient efficacy, with respect to 21 (7.6%) in
the levocetirizine group (P  0.0007 according to the Wil-
coxon test). Other reasons for dropout were represented by
withdrawal of consent for personal reasons (15, 5.5% placebo
patients; 17, 6.1% levocetirizine patients), adverse events (8,
2.9% placebo; 11, 4.0% levocetirizine), and others (8, 2.9%
placebo; 4, 1.4% levocetirizine). One patient receiving pla-
cebo was lost to follow-up.
Patients were enrolled at a randomization visit, after 1
week, if they presented a T5SS 6 of 15 for at least 4 days
during the run-in period. All the randomized patients received
5 mg of levocetirizine or placebo orally each day, starting on
the evening of the second visit and continuing for 6 months.
All the patients included in the study were evaluated at the
end of the first treatment week and again at weeks 4, 12, 18,
26, and 27, after another week’s follow-up.
Patients were excluded if they were pregnant or nursing
mothers, women not using a medically accepted method of
contraception, patients with ear, nose, or throat or eye infec-
tion during the 2 weeks preceding the first visit, and patients
with asthma treated daily with other than an inhaled -agonist
on demand. Patients that presented atopic dermatitis or urti-
caria requiring antihistamine or corticosteroid treatment, with
other ear, nose, or throat diseases such as vasomotor rhinitis
or nasal polyps, other clinically significant diseases such as
glaucoma or cardiovascular or hepatic diseases, or any dis-
order disturbing absorption, distribution, metabolism, or ex-
cretion of levocetirizine, were also excluded.
All the patients could use nasal or ocular cromoglycate
and, in case of unbearable impairment of the allergic rhinitis
symptoms, after a minimum of 4 weeks of treatment, were
permitted a maximum of 20 mg of oral prednisolone once
daily for 5 days, for a maximum of 2 prednisolone courses
during the whole study. Compliance for both study and
rescue medications was evaluated at each visit.
Health-related quality of life is an important parameter
because it considers the effect of both disease and treatment
on a patient’s life as subjectively perceived.
The RQLQ is a disease-specific, validated, and repro-
ducible tool for assessing HRQoL and how symptoms and
treatments affect patients’ physical, social, and emotional
status.10 It is characterized by 28 items and 7 domains. All of
the items have a score ranging from 0 (no trouble) to 6 (major
impairment). The RQLQ was completed at visit 2 (random-
ization) and at visits 3 to 7, or at the end of the study
treatment in case of withdrawal.
The SF-36 is another well-validated questionnaire to
evaluate health status, to assess the impact of various dis-
eases, such as allergic rhinitis,11 and to compare the effects of
various treatments. Through 36 questions, it measures 8
health dimensions domains condensed into 2 physical and
mental health summary measures, with scores ranging from 0
(worst reported health status) to 100 (best reported health
status).12 All the patients had to complete the SF-36 at each
visit, except visit 3 (week 1), after the RQLQ.
Rhinitis symptoms were assessed by using the T5SS.
This total symptom score measures the symptoms normally
responding to antihistamines, such as rhinorrhea, sneezing,
nasal and ocular pruritus, and also nasal congestion, which is
one of the most bothersome symptoms and maybe the most
clinically relevant symptom in patients with PER. Through
the use of electronic diaries, all the patients recorded their
rhinitis symptoms daily, with 4-point scale score ranging
from 0 (absent) to 3 (severe) for each symptom (Minidoc;
Arracel, Sittingbourne, United Kingdom).
The authors also considered the pharmacoeconomic
aspect, including estimates for direct medical cost and indi-
rect cost in the working population due to PER and to
comorbidities such as asthma, sinusitis, otitis media, and
upper respiratory tract infections. Direct costs consisted of
the use of medical resources: hospitalization, physician visits,









Mean (SD) 30.8 (8.8) 29.8 (8.9) 30.3 (8.9)
Median 29.0 28.0 28.2
Minimum-maximum 18.1–70.3 18.0–66.2 18.0–70.3
Duration of PER before
randomization,
years, mean (SD)
12.8 (8.2) 11.9 (7.8) 12.3 (8.0)
Sex, female 158 (57.9%) 152 (54.7%) 310 (56.3%)
Working status
Working 196 (72%) 186 (67%) 382 (69%)
Nonworking 77 (28%) 92 (33%) 169 (31%)
*ITT population.
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and concomitant medications. Indirect costs associated with
PER or comorbidities, assessed through a weekly question-
naire on Minidoc, included absenteeism and presenteeism
(that is, lost of productivity while still present at work). UCB
Pharma clinical trials operations monitored the whole study
and helped in providing the statistical analyses.
A total of 724 patients were included at the screening
visit, of whom 551 patients were randomized to received
levocetirizine or placebo treatment.
Regarding T5SS, a statistically significant difference
was observed for nasal and ocular symptoms just from the
first week after starting the treatment; they remained stable
for the entire duration of the 6-month treatment period. Nasal
congestion was improved significantly after the first month of
treatment and continued for 6 months (Fig. 1).13
The use of cromoglycates, nasal and/or ocular, as res-
cue medications in case of allergic rhinitis impairment, was
higher in the placebo group during the first 4 weeks (62.6%
of the patients receiving placebo versus 49.3% of the patients
treated with levocetirizine; P 0.002); moreover, an increas-
ing trend of rescue medication use was observed in the
placebo group over the entire 6 months of treatment: 13.6%
versus 10.8% for prednisolone (P 0.362) and 75.8% versus
69.4% (P  0.104) for cromoglycates.
Levocetirizine improved QoL assessed by the RQLQ
questionnaire and SF-36 as early as the first week of treat-
ment. This improvement of the levocetirizine group versus
placebo was confirmed for each RQLQ domain (Table 2,
Table 3). SF-36 summary scores followed a similar course.9
In the group treated with levocetirizine, mean changes from
baseline of physical and mental summary scores ranged from
3.65 to 5 and from 3.83 to 5.97, respectively, with respect to
the placebo group where they ranged from 1.61 to 3.37 and
from 2.79 to 3.99. Between the two study groups, significant
FIGURE 1. Change in individual symptom scores over a period of 6 months.




After 4 Weeks of Treatment/
Adjusted Mean (SEM)†
Difference vs Placebo (95% CI)/
Adjusted Mean P
RQLQ overall score
Placebo 252 3.06 (0.94) 1.01 (0.07)
Levocetirizine (5 mg) 257 3.04 (0.92) 1.49 (0.07) 0.48 (0.29–0.67) 0.001
T5SS
Placebo 271 8.90 (2.26) 2.40 (0.15)
Levocetirizine (5 mg) 276 9.02 (2.28) 3.54 (0.15) 1.14 (0.75–1.52) 0.001
*Number of ITT patients with nonmissing values at baseline and under treatment.
†Mean change from baseline, adjusted for baseline score and country.
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differences were recorded about mean changes after 3 and 4.5
months for the mental component summary score (both P
values 0.01) and after 4 weeks and 3, 4.5, and 6 months for
the physical component summary score (all P values 0.01).
In a parallel manner to the RQLQ overall score, subjective
improvement in the health condition seemed related to symp-
toms relief.
Comorbidities were considered during the study: the
most frequent were represented by upper respiratory infec-
tions and asthma. In an exploratory analysis of the XPERT
study, levocetirizine reduced the percentage of patients with
at least one asthma event to 7.4 (from 13.6 for placebo, P 
0.04) and reduced the mean number of asthma medication
events from 0.23 per placebo patient to 0.11 (P  0.001).13
Levocetirizine was well tolerated and safe for a greater
than 6-month period, making it suitable for chronic treatment.
In the placebo group, 193 (70.7%) patients, with respect to
192 (69.1%) of the active group, recorded at least one adverse
event at some point during the 6-month study. Adverse events
were commonly represented by headache (23.2% placebo
versus 24.5% levocetirizine), pharyngitis (20.5% versus
19.8%), influenza-like symptoms (13.9% versus 14.0%), fa-
tigue (7.0% versus 8.6%), sleepiness (1.8% versus 6.8%) and
gastroenteritis (5.1% versus 2.9%). No hospitalizations
occurred.
Levocetirizine treatment also caused a reduction of the
overall cost of the disease. All the cost parameters (direct and
indirect) in fact presented a significant improvement in pa-
tients treated with levocetirizine versus placebo group. A
long-term levocetirizine therapy presented lower costs com-
pared with those of the untreated PER and its comorbidities
(€350 per patient per month). Loss of work days was lower in
levocetirizine than placebo group (0.18 days per patient per
month versus 0.45 days per patient per month). Levocetiriz-
ine treatment produced cost savings to society of more than
€150 per patient per month, consequent to patients’ major
ability to maintain work and daily activities (Table 4).14
In conclusion, XPERT was the first prospective study
of levocetirizine in ARIA-defined PER. This multicenter,
multinational, randomized, double-blind, placebo-controlled,
parallel-group study was innovative not only in terms of
definition of allergic rhinitis but also for the large sample
(550 patients), long-lasting treatment period (26 weeks), the
study design, and the aim of the study (clinical efficacy, QoL,
adverse events, comorbidities, and pharmacoeconomy/eco-
nomic costs). Furthermore, it was closer to the real life and
PER study model with respect to previous trials. PER fre-
quently has debilitating symptoms that interfere with patients
QoL, their daily activities, and their productivity. A rapid
onset of action, effective and long-lasting treatment like
levocetirizine appears to have, is very important for a satis-
fying treatment of PER. Levocetirizine is effective against all
the symptoms related to allergic rhinitis and seems also able
to reduce the minimal persistent inflammation characterizing
patients’ mucosal structures affected by PER.
Levocetirizine is well-tolerated, safe, and suitable for
continuous and long-lasting treatment. Furthermore, a
long-term treatment with levocetirizine reduces overall
TABLE 3. Changes of the RQLQ Domains at 4 Weeks From Baseline
Domain







(SEM) Adjusted Mean P
Activities 241 1.36 (0.10) 248 2.08 (0.10) 0.73 (0.47–0.99) 0.001
Emotions 252 0.81 (0.07) 257 1.16 (0.07) 0.35 (0.17–0.54) 0.001
Eye symptoms 252 0.91 (0.09) 257 1.40 (0.09) 0.48 (0.26–0.70) 0.001
Non–hay fever symptoms 252 0.83 (0.08) 257 1.21 (0.08) 0.38 (0.18–0.57) 0.001
Nasal symptoms 252 1.10 (0.09) 257 1.64 (0.09) 0.54 (0.31–0.77) 0.001
Practical problems 252 1.50 (0.10) 257 2.06 (0.10) 0.56 (0.30–0.82) 0.001
Sleep 252 0.86 (0.09) 257 1.35 (0.09) 0.50 (0.27–0.73) 0.001
*Number of ITT patients with nonmissing values at baseline and under treatment.
†Mean change from baseline, adjusted for baseline score and country.
TABLE 4. Mean Direct and Indirect Costs Per Month Per Working Patient
Placebo Mean €
(95% CI) (N  196)
Levocetirizine (5 mg) Mean €




Total direct medical costs for PER 5.32€ (4.43, 6.42) 16.81€ (15.94, 18.13) 11.50€ (10.06, 13.03) 0.001
Total direct medical costs for comorbidities 2.72€ (1.82, 4.20) 1.77€ (1.14, 3.04) 0.96€ (2.60, 0.40) 0.18
Indirect costs
Absenteeism 45.70€ (32.02, 75.00) 18.57€ (13.75, 26.00) 27.14€ (55.78, 12.10) 0.001
Presenteeism 106.54€ (86.97, 132.86) 71.04€ (56.16, 92.43) 35.50€ (65.21, 7.01) 0.02
Total costs 160.27€ (129.93, 204.54) 108.18€ (91.55, 131.78) 52.09€ (98.18, 13)
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costs (direct and indirect costs) for both PER and associ-
ated comorbidities, with a consequently important impact
on socioeconomic aspects.
Levocetirizine thus satisfies all the ARIA/EAACI effi-
cacy and safety criteria and is suitable for long-term treatment
of PER as a first-line drug among the second-generation
antihistamines.
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